World news – AU – Zacks: Brokerages Anticipate Exelixis, Inc (NASDAQ: EXEL) to announce earnings of $ 0 04 per share

Subscribe to MarketBeat All Access to access MarketBeat’s full suite of search tools:

Wall Street analysts expect Exelixis, Inc. (NASDAQ: EXEL) to report earnings of $ 0 04 per share for the current quarter, Zacks Reports Five analysts have released estimates of Exelixis earnings, with the highest estimate of earnings per share at $ 0 07 and the lowest estimate at (0 $ 02) Exelixis posted earnings of $ 0 $ 22 per share in the same quarter last year, indicating a negative year-over-year growth rate of 818%. The company is set to release its next quarterly earnings report on Tuesday, February 23

According to Zacks, analysts expect Exelixis to produce a full-year dividend of $ 0 35 per share for the current fiscal year, with EPS estimates ranging from $ 0 19 to $ 0 $ 51 for the next fiscal year. Analysts expect the company to generate earnings of $ 0 $ 74 per share, With EPS estimates ranging from $ 0 35 to $ 1 06 EPS calculations from Zacks Investment Research are average based on a survey of sell-side research analysts who follow Exelixis

Exelixis (NASDAQ: EXEL) released its latest earnings results on Thursday, Nov. 5 The biotech company reported ($ 0 10) earnings per share for the quarter, below analysts’ consensus estimate of $ 0 $ 01 by ($ 011) Exelixis achieved a return on equity of 1640% With a net margin of 2,821%, the company generated revenues of $ 231 $ 10 million for the quarter, compared to consensus estimates of $ 215 $ 40 million during the same quarter of the previous year, the company reported $ 0 $ 34 EPS Exelixis revenue decreased 149% year-over-year

Several research analysts recently focused on EXEL shares Piper Sandler raised the target price for Exelixis shares from $ 30 from $ 00 to $ 33 00 and gave the stock a « overweight » rating in Monday September 21 BidaskClub downgraded Exelixis from a « sell » rating to a « sell » rating Strong Sell ”In a Research Report Monday, November 2, Oppenheimer boosted his price target on Exelixis from $ 33.00 to $ 37.00 and gave the stock an“ outperforming ”rating in Monday’s report, September 21 Morgan Stanley increased his price target on Exelixis stocks from $ 23 from $ 00 to $ 29 Finally, Stifel Nicolaus strengthened the target price for Exelixis shares from $ 26 from $ 00 to $ 27 00 and gave the company an ‘equal’ rating In a report released on Monday, October 26th, an analyst evaluated the stock with a sell rating. Five assigned a hold rating and eight issued a buy stock rating The stock currently has a « buy » consensus rating and an average target price of $ 29 83 (adsbygoogle = windowadsbygoogle || []) push ({});

In other news, EVP Jeffrey Hessekiel sold 39,742 shares of the company in a deal that took place on Wednesday, October 21. The stock was sold at an average price of $ 21 95, for a total transaction of $ 872,336. 90 The deal was revealed in a file with the SEC, which can also be accessed through this link. Chief Financial Officer Christopher J. Senner sold 20,000 shares of the company’s shares in a deal that took place on Tuesday. September 15 Shares were sold at an average price of $ 25 00, with a total value of $ 500,000 00 The disclosure of this sale can be found here Insiders sold a total of 74,422 shares of the company’s shares valued at $ 1,744,438 over the past three months. Corporations own 450% of the company’s shares

Hedge funds and other institutional investors recently bought and sold shares of the company State Street Corp. strengthened its position in Exelixis by 26% during the first quarter State Street Corp. now owns 11,354,975 shares of the biotech company valued at 195,533, $ 000 after acquisition of an additional 293,028 shares during the last quarter Bank of New York Mellon Corp boosted its stake in Exelixis by 03% during the second quarter Bank of New York Mellon Corp now owns 3,332,392 shares of the biotech company $ 79,111,000 after purchasing an additional 10,960 shares during the period Avidity Partners Management LP grew its Exelixis holdings by 1481% during the second quarter Avidity Partners Management LP now owns 2,694,070 shares of the biotech company valued at $ 63,957,000 after purchasing 1,608,070. & Blair William Inc raised its Exelixis position by 143% in the third quarter, Blair William & Inc. now holds 2,395,808 biotech shares valued at $ 58,578,000 after buying 299,453 Extra shares during the period Finally, Stephens Investment Management Group LLC raised its position in Exelixis by 42% in the second quarter Stephens Investment Management Group LLC now owns 1,488,622 shares of the biotech company valued at $ 35,340,000 after purchasing An additional 60,601 shares during the period 8,162% of the shares are owned by institutional investors

NASDAQ EXEL shares opened at $ 20 71 on Monday, market capitalization is $ 6 98 billion, PE ratio 4315, price-to-earnings growth ratio of 170 and a beta of 143 Exelixis has a year-long low of $ 13 67 and a year high of $ 27 of $ 80 Company’s fifty-day moving average price $ 23 32 and a 200-day moving average price of $ 2346

Exelixis, Inc., a biotechnology company focused on oncology, is focused on discovering, developing, and commercially commercializing new drugs for cancer treatment in the United States. The company’s products include CABOMETYX tablets to treat patients with advanced RCC who have received pre-existing antigenic therapy. Bowls COMETRIQ capsules for the treatment of patients with progressive and diffuse medullary thyroid cancer

This instant news alert was created by narrative science technology and financial data from MarketBeat to provide readers with the fastest and most accurate reports. This story has been reviewed by MarketBeat’s editorial team before publication. Please send any questions or comments about this story to [email protected]

Almost everyone loves a company that makes big profits Who of us doesn’t like getting a check every three months just to own a share – especially if that stock returns you 4%, 5%, or even 10% of its share price in annual income each year? In a world where 10-year Treasuries yield just over 2%, it seems hard to go wrong buying a stock that yields well above the rates applicable to fixed-income assets Unfortunately, the market rarely offers a free lunch.

While high-yielding stocks may have a lot of appeal in the near term, those same high returns can indicate a significant risk in the future. In some cases, this could mean that the company’s profits will stop growing or not grow as quickly as they used to. Even worse, the company can reduce its profits, reduce the income it gets from owning shares, and reduce the value of the shares it owns.

4% surplus returns may seem like an easy opportunity to increase the investment income you receive, but high-yielding stocks can often act as a reading that tracks the rhythm of unsuspecting investors It is not always easy to tell the difference.

This slideshow highlights 10 high-yield dividend stocks that pay an unsustainable large percentage of their earnings in the form of dividends that all of these companies pay more than 100% of their earnings per share in the form of dividends, an indication that the announced high return will not last. Most likely

Complete the form below to receive the latest headlines and analyst recommendations on your stocks through our free daily email newsletter:

Subscribe to MarketBeat All Access to access MarketBeat’s complete search toolkit:

View the latest news, buy / sell ratings, SEC deposits and insider transactions for your stocks Compare your portfolio performance against leading indices and get personalized stock ideas based on your portfolio

Get daily stock insights from top-performing Wall Street analysts Get short-term trading ideas from the MarketBeat Idea Engine See the most active stocks on social media with MarketBeat’s Hot Stock Report

Select stocks that meet your criteria with seven unique stock screeners See what’s happening in the market right now with real-time news feed from MarketBeat Export data to Excel for your own analysis

Looking for new stock ideas? Want to see which stocks are moving? See our full collection of financial calendars and market spreadsheets, all for free

Get free global investing education from MarketBeat Learn about financial terms, types of investments, trading strategies and more

MarketBeat enables individual investors to make better trading decisions by providing real-time financial data and objective market analysis whether you are looking for analyst assessments, corporate buybacks, dividends, dividends, economic or financial reports, or Insider deals, IPOs, SEC deposits, or stock splits, MarketBeat has the objective information you need to analyze which stock I know more

© American Consumer News, LLC dba MarketBeat® 2010-2020 All rights reserved
326 E 8th St # 105, Sioux Falls, SD 57103 | [Email protected] | (844) 978-6257
MarketBeat does not provide financial advice nor does it issue recommendations or offers to buy shares or sell any security I know more
Don’t sell my information

© 2020 Market data provided at least 10 minutes late and hosted by Barchart Solutions Basic company data provided by Morningstar and Zacks Investment Research The information is provided « as is » and for informational purposes only, not for commercial or advice purposes, and is delayed to see all exchange delays and terms Use, please see the disclaimer

Enter your email address below to receive a brief daily summary of analyst promotions, rating cuts and new coverage with MarketBeat Free daily email newsletter

NASDAQ: EXEL, Earnings, Exelixis, NASDAQ, Stock